Clover Health Investments Corp. [NASDAQ: CLOV] slipped around -0.05 points on Monday, while shares priced at $3.25 at the close of the session, down -1.52%. The company report on August 8, 2022 that Clover Health Reports Second Quarter 2022 Financial Results.
China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal
Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.
Simply click here and the name & trading symbol are yours.
Second quarter total revenue was $846.7 million compared to $412.5 million in second quarter 2021.
Lives under Clover Management grew to ~255,000 from ~129,000 year-over-year.
Clover Health Investments Corp. stock is now -12.63% down from its year-to-date (YTD) trading value. CLOV Stock saw the intraday high of $3.32 and lowest of $3.16 per share. The company’s 52-week high price is 11.13, which means current price is +66.67% above from all time high which was touched on 01/03/22.
Compared to the average trading volume of 8.91M shares, CLOV reached a trading volume of 7019460 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Clover Health Investments Corp. [CLOV]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CLOV shares is $3.58 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CLOV stock is a recommendation set at 3.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Cowen have made an estimate for Clover Health Investments Corp. shares, keeping their opinion on the stock as Market Perform, with their previous recommendation back on February 02, 2022. While these analysts kept the previous recommendation, Canaccord Genuity raised their target price to Buy. The new note on the price target was released on February 02, 2022, representing the official price target for Clover Health Investments Corp. stock. Previously, the target price had yet another raise to $3, while SVB Leerink analysts kept a Mkt Perform rating on CLOV stock. On January 10, 2022, analysts decreased their price target for CLOV shares from 9 to 3.50.
The Average True Range (ATR) for Clover Health Investments Corp. is set at 0.23, with the Price to Sales ratio for CLOV stock in the period of the last 12 months amounting to 0.57. The Price to Book ratio for the last quarter was 3.61, with the Price to Cash per share for the same quarter was set at 1.16.
How has CLOV stock performed recently?
Clover Health Investments Corp. [CLOV] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -4.41. With this latest performance, CLOV shares gained by 30.52% in over the last four-week period, additionally plugging by 25.00% over the last 6 months – not to mention a drop of -60.46% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CLOV stock in for the last two-week period is set at 60.22, with the RSI for the last a single of trading hit 60.35, and the three-weeks RSI is set at 59.20 for Clover Health Investments Corp. [CLOV]. The present Moving Average for the last 50 days of trading for this stock 2.58, while it was recorded at 3.10 for the last single week of trading, and 3.38 for the last 200 days.
Clover Health Investments Corp. [CLOV]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Clover Health Investments Corp. [CLOV] shares currently have an operating margin of -37.11. Clover Health Investments Corp.’s Net Margin is presently recorded at -38.21.
Return on Equity for this stock declined to -88.46, with Return on Assets sitting at -65.05.
Clover Health Investments Corp.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.20 and a Current Ratio set at 1.20.
Earnings analysis for Clover Health Investments Corp. [CLOV]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CLOV. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Clover Health Investments Corp. go to 19.10%.
Insider trade positions for Clover Health Investments Corp. [CLOV]
There are presently around $400 million, or 26.40% of CLOV stock, in the hands of institutional investors. The top three institutional holders of CLOV stocks are: VANGUARD GROUP INC with ownership of 32,095,012, which is approximately 23.028% of the company’s market cap and around 3.10% of the total institutional ownership; BLACKROCK INC., holding 24,435,025 shares of the stock with an approximate value of $79.41 million in CLOV stocks shares; and STATE STREET CORP, currently with $25.84 million in CLOV stock with ownership of nearly 311.373% of the company’s market capitalization.
Positions in Clover Health Investments Corp. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 94 institutional holders increased their position in Clover Health Investments Corp. [NASDAQ:CLOV] by around 51,454,910 shares. Additionally, 69 investors decreased positions by around 53,069,185 shares, while 48 investors held positions by with 18,593,531 shares. The mentioned changes placed institutional holdings at 123,117,626 shares, according to the latest SEC report filing. CLOV stock had 40 new institutional investments in for a total of 5,305,086 shares, while 34 institutional investors sold positions of 29,078,597 shares during the same period.